APP下载

酮替芬和孟鲁司特治疗支气管哮喘的疗效比较

2018-06-06吴宏敏

健康必读·下旬刊 2018年5期

吴宏敏

【摘 要】目的:探讨并分析舒利迭联合酮替芬和孟鲁司特对支气管哮喘的临床治疗效果。方法:选取我院64例支气管哮喘患者,给予治疗组患者舒利迭联合酮替芬治疗,给予对照组患者舒利迭联合孟鲁司特治疗。观察并比较两组患者的药物治疗效果。结果:与对照组相比,治疗组患者的哮喘控制测试评分显著增高(P<0.05);治疗组患者的不良反应发生率明显降低(P<0.05)。结论:舒利迭联合酮替芬治疗支气管哮喘临床效果更好,不良反应发生率低,值得临床推广应用。

【关键词】支气管哮喘,舒利迭联合酮替芬,不良反应

Comparison of the curative effect of ketotefen and montelukast in the treatment of bronchial asthma

WuHongmin(Department of internal medicine of Shahe source community health service center, Chengdu, Sichuan, 610081)

Abstract Objective: Study and analysis of seretide combined with montelukast and ketotifen treatment effect on bronchial asthma.Methods:Select 64 cases of bronchial asthma patients, the patients in the treatment group were given Seretide combined with ketotifen treatment, the control group was given Seretide combined with montelukast treatment. The therapeutic effect of two groups of patients was observed andcompared.Result:Compared with the control group, the asthma control test score in the treatment group was significantly higher (P<0.05), and the incidence of adverse reactions in the treatment group was significantly lower (P<0.05).Conclusion:Seretide combined with ketotifen treatment of bronchial asthma has better clinical efficacy, low incidence of adverse reactions, it is worthy of clinical application.

Key words: bronchial asthma, Seretide combined with ketotifen, adverse reaction

【中图分类号】R453 【文献标识码】A 【文章编号】1672-3783(2018)05-03--01

支气管哮喘是一种常见的慢性呼吸道疾病,是一种由多种细胞和细胞组分共同参与而引起的机体慢性炎症,该病的发病机制较复杂,诱发因素较多,比如生活环境的改变,空气污染,肺炎感染等[1]。该病的主要临床症状为患者胸闷,咳嗽,严重者甚至呼吸困难而造成休克等,严重威胁患者的身体健康和生活质量。因为该病易反复发作,造成临床治疗效果不理想,治疗比较困难。舒利迭是临床中治疗支气管哮喘的常用药物,该药物能够有效缓解哮喘的临床症状。孟鲁司特是白三烯的受体拮抗剂,白三烯是引发支气管哮喘的一种重要炎性介质,因此孟鲁司特对白三烯的活性具有抑制作用,也成为治疗支气管哮喘的要我之一[2]。酮替芬是以前治疗哮喘常见的药物之一,该药物能够抑制组胺的释放,还能抑制体内抗原的活性。为探讨舒利迭联合酮替芬对支气管哮喘的治疗效果,本研究选取64例支气管哮喘患者为研究对象,随机分为治疗组(32例)和对照组(32例),治疗组给予舒利迭联合酮替芬药物对患者进行治疗,对照组采用舒利迭联合孟鲁司特药物进行治疗,現将结果报道如下。……

登录APP查看全文